PaySign shares fell 18.9% after earnings, with the planned loss of payment processing at 113 plasma centers likely weighing on investors despite rapid patient-affordability growth. The transition is expected to be completed in Q4, and management said it expects new centers to offset the loss over the next couple of quarters.
Shares plunged 12.9% as investors reacted negatively to the company’s cautious outlook and operational headwinds despite reported revenue growth. The disconnect likely stems from Q1 being described as “operationally constrained” and uncertainty around the impact of center closures in the plasma business.